EA200601871A1 - Способы лечения аутоиммунных и воспалительных заболеваний - Google Patents

Способы лечения аутоиммунных и воспалительных заболеваний

Info

Publication number
EA200601871A1
EA200601871A1 EA200601871A EA200601871A EA200601871A1 EA 200601871 A1 EA200601871 A1 EA 200601871A1 EA 200601871 A EA200601871 A EA 200601871A EA 200601871 A EA200601871 A EA 200601871A EA 200601871 A1 EA200601871 A1 EA 200601871A1
Authority
EA
Eurasian Patent Office
Prior art keywords
treatment
autoimmune
methods
inflammatory diseases
autoimmune diseases
Prior art date
Application number
EA200601871A
Other languages
English (en)
Other versions
EA012725B1 (ru
Inventor
Бернар Маш
Иянн Деан
Мари Коско-Вильбуа
Original Assignee
Новиммун С.А.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новиммун С.А. filed Critical Новиммун С.А.
Publication of EA200601871A1 publication Critical patent/EA200601871A1/ru
Publication of EA012725B1 publication Critical patent/EA012725B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Настоящее изобретение относится к способу лечения аутоиммунных заболеваний и/или воспалительных расстройств.
EA200601871A 2004-04-06 2005-04-06 Применение анти-cd3 антитела для изготовления лекарственного средства для лечения или облегчения симптома воспалительного расстройства и способ лечения или облегчения воспалительного расстройства EA012725B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55994404P 2004-04-06 2004-04-06
PCT/US2005/011767 WO2005099755A2 (en) 2004-04-06 2005-04-06 Methods of treating autoimmune and inflammatory diseases

Publications (2)

Publication Number Publication Date
EA200601871A1 true EA200601871A1 (ru) 2007-04-27
EA012725B1 EA012725B1 (ru) 2009-12-30

Family

ID=35150504

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200601871A EA012725B1 (ru) 2004-04-06 2005-04-06 Применение анти-cd3 антитела для изготовления лекарственного средства для лечения или облегчения симптома воспалительного расстройства и способ лечения или облегчения воспалительного расстройства

Country Status (20)

Country Link
US (1) US20050265993A1 (ru)
EP (1) EP1737490B1 (ru)
JP (1) JP4812748B2 (ru)
KR (1) KR20070036035A (ru)
CN (2) CN1972714B (ru)
AT (1) ATE470453T1 (ru)
AU (1) AU2005232653B2 (ru)
CA (1) CA2563260C (ru)
DE (1) DE602005021766D1 (ru)
DK (1) DK1737490T3 (ru)
EA (1) EA012725B1 (ru)
ES (1) ES2348984T3 (ru)
HK (1) HK1099525A1 (ru)
IL (2) IL178478A (ru)
MX (1) MXPA06011526A (ru)
NO (2) NO340627B1 (ru)
PT (1) PT1737490E (ru)
UA (2) UA89780C2 (ru)
WO (1) WO2005099755A2 (ru)
ZA (1) ZA200608884B (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4939899B2 (ja) * 2006-10-30 2012-05-30 オムロンオートモーティブエレクトロニクス株式会社 導電端子の溶接方法、および導電端子構造
CN101687915B8 (zh) † 2007-04-03 2018-08-03 安进研发（慕尼黑）股份有限公司 跨物种特异性CD3-ε结合结构域
RU2571063C2 (ru) * 2010-05-24 2015-12-20 Индена С.П.А. Полисахарид семени тамаринда для применения в лечении микробных инфекций
JP2014500879A (ja) * 2010-11-16 2014-01-16 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｃｍａ発現に相関性を有する疾患を治療する因子及び方法
JP2015091761A (ja) * 2012-02-23 2015-05-14 国立大学法人大阪大学 中枢神経の損傷を治療するための組成物およびその利用
US9664690B1 (en) * 2013-08-28 2017-05-30 The National Institute For Biotechnology I Molecular diagnostic kits for evaluating stress
AU2019359869A1 (en) * 2018-10-16 2021-05-27 Board Of Regents, The University Of Texas System Identification and targeting of pathogenic extracellular matrix for diagnosis and treatment of cancer and other diseases
JP2022512709A (ja) * 2018-10-31 2022-02-07 ティジアーナ ライフ サイエンシズ パブリック リミティド カンパニー 炎症性疾患及び自己免疫疾患を処置する組成物及び方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025477A (en) * 1986-03-31 2000-02-15 Calenoff; Emanuel Atherosclerotic plaque specific antigens, antibodies thereto, and uses thereof
CA2162586C (en) * 1993-05-13 2006-01-03 David J. Grainger Prevention and treatment of pathologies associated with abnormally proliferative smooth muscle cells
US7041289B1 (en) * 1997-12-05 2006-05-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Method for treating established spontaneous auto-immune diseases in mammals
GB2380127A (en) * 2001-09-26 2003-04-02 Isis Innovation Treatment of chronic joint inflammation
US20030216551A1 (en) * 2002-03-08 2003-11-20 Diabetogen Biosciences Inc. Fully human anti-CD3 monoclonal antibodies
CA2552891A1 (en) * 2004-01-08 2005-08-04 Regents Of The University Of California Regulatory t cells suppress autoimmunity

Also Published As

Publication number Publication date
NO20064896L (no) 2006-11-06
IL178478A (en) 2010-12-30
US20050265993A1 (en) 2005-12-01
CN1972714A (zh) 2007-05-30
CA2563260A1 (en) 2005-10-27
AU2005232653A1 (en) 2005-10-27
ES2348984T3 (es) 2010-12-21
IL209338A0 (en) 2011-01-31
CA2563260C (en) 2013-05-28
AU2005232653B2 (en) 2010-12-16
ATE470453T1 (de) 2010-06-15
IL178478A0 (en) 2007-02-11
WO2005099755A3 (en) 2006-04-27
HK1099525A1 (en) 2007-08-17
JP2007532565A (ja) 2007-11-15
WO2005099755A2 (en) 2005-10-27
CN102847149A (zh) 2013-01-02
CN102847149B (zh) 2016-01-20
EP1737490A2 (en) 2007-01-03
ZA200608884B (en) 2008-06-25
PT1737490E (pt) 2010-08-31
EP1737490B1 (en) 2010-06-09
DK1737490T3 (da) 2010-10-04
UA103594C2 (ru) 2013-11-11
UA89780C2 (ru) 2010-03-10
EA012725B1 (ru) 2009-12-30
NO20170737A1 (no) 2006-11-06
DE602005021766D1 (de) 2010-07-22
NO340627B1 (no) 2017-05-15
CN1972714B (zh) 2012-10-03
JP4812748B2 (ja) 2011-11-09
KR20070036035A (ko) 2007-04-02
MXPA06011526A (es) 2007-03-21

Similar Documents

Publication Publication Date Title
EA200601871A1 (ru) Способы лечения аутоиммунных и воспалительных заболеваний
CY1120384T1 (el) Απταμερη θεραπευτικα χρησιμα στην αντιμετωπιση των σχετικων με το συμπληρωμα διαταραχων
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
EA200700333A1 (ru) Терапевтические применения ингибиторов rtp801
ATE540949T1 (de) Substituierte pteridine zur behandlung von entzündlichen erkrankungen
DK3530673T3 (da) Humaniserede anti-beta7-antagonister og anvendelser deraf
IS8451A (is) Aðferðir og hvarfefni til að meðhöndla ónæmisbólgusjúkdóma
IS8410A (is) Aðferðir og hvarfefni til að meðhöndla ónæmisbólgusjúkdóma
DE602005023172D1 (de) Hydantoinderivate zur behandlung von entzündlichen erkrankungen
DK1836169T3 (da) Sammensætninger og fremgangsmåder til behandling af celleproliferationslidelser
EA200900802A1 (ru) Способы и композиции для лечения амилоидных заболеваний
DK1706112T3 (da) Fremgangsmåder til at behandle en inflammatorisk-beslægtet sygdom
NO20034056D0 (no) Proliferative sykdommer
DK1615952T3 (da) Fremgangsmåder til behandling af betændelsestilstande med specifikke, til humant angiopoietin-2-bindende midler
DK1644021T3 (da) Fremgangsmåder og sammensætninger til behandlingen af gastrointestinale sygdomme
EA200801244A1 (ru) Применение sdf-1 для лечения и/или профилактики неврологических заболеваний
NO20055563L (no) Midler for behandlingen av lavere abdominale lidelser
NO20055309L (no) Slurp-1 samrnensetninger og fremgangsmater for anvendelse derav
DK1895017T3 (da) Anvendelse af A33-antigener og JAM-IT
EA200501528A1 (ru) Применение кластерина для лечения и/или профилактики периферических неврологических заболеваний
ATE410235T1 (de) Behandlung von ballastwasser
ATE498010T1 (de) Natürliche igm-antikörper und inhibitoren davon
ATE446757T1 (de) 1-ä2h-1-benzopyran-2-one-8-ylü- piperazinderivative zur behandlung von bewegungsstörungen
NO20072048L (no) Anvendelse av IL-17F for behandling og/eller forebygging av neurologiske sykdommer.
EA200600314A1 (ru) Использование растворимого cd164 при воспалительных и/или аутоимунных нарушениях